Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week, multi-center, randomized, prospective, open-label, blinded rater, crossover study of the effects of immediate-release carbidopa/levodopa versus carbidopa/levodopa/entacapone on markers of event-related potentials (ERPs) in patients with idiopathic Parkinson's disease and end-of-dose wearing off.

Trial Profile

A 12-week, multi-center, randomized, prospective, open-label, blinded rater, crossover study of the effects of immediate-release carbidopa/levodopa versus carbidopa/levodopa/entacapone on markers of event-related potentials (ERPs) in patients with idiopathic Parkinson's disease and end-of-dose wearing off.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2012

At a glance

  • Drugs Levodopa/carbidopa; Levodopa/carbidopa/entacapone
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Jun 2012 Status changed from discontinued to completed as reported by European Clinical Trials Database.
    • 23 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-003134-42).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top